Announcing Viking Therapeutics' $24 Million Funding Round for Breakthrough Metabolic Disorder Therapies

Viking Therapeutics, Inc.

(Nasdaq:VKTX), a pioneering clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders, is thrilled to announce the successful closing of a $24 million funding round.

This significant investment will bolster the advancement of Viking’s promising research pipeline and enhance its ability to bring groundbreaking therapies to market.

Currently, the company is making strides in clinical development with its lead candidate, a non-steroidal selective androgen receptor modulator (SARM), which is undergoing a Phase 2 trial aimed at enhancing recovery outcomes for patients following hip fracture surgery.

Additionally, Viking is advancing its thyroid receptor beta (TRb) agonist platform, which is also in Phase 2 trials, targeting lipid disorders such as hypercholesterolemia and critical liver diseases, including non-alcoholic steatohepatitis (NASH).

The funding will not only support these key therapeutic candidates but will also facilitate exploration into rare diseases like glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy (X-ALD).

With this new infusion of capital, Viking Therapeutics is poised to accelerate its research efforts, driving the development of first-in-class treatments that can significantly improve patient outcomes in areas of high unmet medical need.

As always, we remain committed to scientific excellence and innovation, and we look forward to sharing future milestones with our stakeholders.

For more information about our ongoing projects, please visit our website at http://www.vikingtherapeutics.com.